Screener
Merck & Co. MRK Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Merck & Co. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Merck & Co.’s 10-Q, filed May 4, 2026. Open the filing →
- Filed
- May 4, 2026, 4:10 PM EDT
- Fiscal quarter
- Q3 FY2028
- Calendar quarter
- Q3 2028
- Accession
- 0001628280-26-029802
FAQ
- What is Merck & Co.'s cash & equivalents?
- Merck & Co. (MRK) reported cash & equivalents of $5.4B in Q1 2026.
- How has Merck & Co.'s cash & equivalents changed year-over-year?
- Merck & Co.'s cash & equivalents decreased by 38.2% year-over-year, from $8.73B to $5.4B.
- What is the long-term trend for Merck & Co.'s cash & equivalents?
- Over 5 years (2020 to 2025), Merck & Co.'s cash & equivalents has grown at a 12.5% compound annual growth rate (CAGR), from $8.15B to $14.69B.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Merck & Co.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude